

APC anti-human CD2

Catalog # / Size: 2146115 / 25 tests
2146120 / 100 tests

Clone: TS1/8

Isotype: Mouse IgG1, κ


Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Workshop Number: V S025

Concentration: Lot-specific



Human peripheral blood lymphocytes stained with CD3 Brilliant Violet 421™ and anti-human CD2 (clone TS1/8) APC (top) or mouse IgG1 APC isotype control (bottom).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: Additional reported applications (for the relevant formats) include: blocking of T cell activation, and partial blocking of B cell costimulation². The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 309212).

Application References:

- Schlossman S, et al. Eds.1995. Leucocyte Typing V Oxford University Press. New York.
- Hughes CCW, et al. 1996. *J. Biol. Chem.* 271:5369.

Description: CD2 is a 50 kD type I transmembrane glycoprotein also known as LFA-2, T11, and sheep red blood cell receptor (SRBC-R). This immunoglobulin superfamily member is expressed on thymocytes, T lymphocytes, NK cells, and thymic B cell subsets. The major ligand for CD2 is CD58 (also known as LFA-3). CD2 has also been reported to bind CD48, CD59, and CD15. CD2 plays a critical role in alternative T cell activation, T cell signaling, and cell-cell adhesion.

- Antigen**
- References:**
1. Bell G, *et al.* 1995. *J. Immunol.* 155:2805.
 2. Bierer B, *et al.* 1989. *Annu. Rev. Immunol.* 7:579.
 3. Moingeon P, *et al.* 1989. *Immunol. Rev.* 111:111.